Operators, scientists, and strategists
Thirteen years of development, backed by a team with deep expertise across biotech, regulatory affairs, clinical development, and commercial operations.
Our team
Wendy Komac
20+ years of multi-industry executive leadership. 13+ years bringing LathMize® NAD+ from the bench to the bedside.
Filip Pinter
12+ years financial expertise. Senior Investment Officer at New York State Common Retirement Fund.
John Pierce
25+ years global logistics and operations. Managed $20B DoD logistics contract.
Alina Aron
15+ years in M&A. Advised 150+ startups on transactions across healthcare and technology.
Lynne McGrath, PhD
30+ years pharmaceutical regulatory. Former senior executive, global drug approvals at Novartis. Co-author of the RENEWAL-NAD+ trial.
Waylon Hastings, PhD
10+ years aging and healthspan research. Assistant Professor of Nutrition, Texas A&M. Co-first author of the RENEWAL-NAD+ trial.
Rocco Crapis, D.C.
Recognized for precision care of high-profile and elite performers.
Michael Leitz-Langan, MD, MSL-BC
Career that spans clinical medicine, geriatrics, medical affairs, and scientific communication.
Anne Marie Morano, MSHA
Clinical research operations leader with 25+ years driving strategy, compliance, and execution.
Phil Mansour
30+ years disruptive tech. Founding CEO of Alzamend Neuro, CEO of MTIX International.
Henry Van den Berg
20+ years clinical development. Former SVP R&D and Medical Affairs at US WorldMeds.
Working with
ALS Therapy Development Institute
Nonprofit biotech advancing ALS treatments. Collaborating on preclinical studies of BRY101 and BRY102.